Targeted Methylation of the Epithelial Cell Adhesion Molecule (EpCAM) Promoter to Silence Its Expression in Ovarian Cancer Cells

The Epithelial Cell Adhesion Molecule (EpCAM) is overexpressed in many cancers including ovarian cancer and EpCAM overexpression correlates with decreased survival of patients. It was the aim of this study to achieve a targeted methylation of the EpCAM promoter and silence EpCAM gene expression using an engineered zinc finger protein that specifically binds the EpCAM promoter fused to the catalytic domain of the Dnmt3a DNA methyltransferase. We show that transient transfection of this construct increased the methylation of the EpCAM promoter in SKOV3 cells from 4–8% in untreated cells to 30%. Up to 48% methylation was observed in stable cell lines which express the chimeric methyltransferase. Control experiments confirmed that the methylation was dependent on the fusion of the Zinc finger and the methyltransferase domains and specific for the target region. The stable cell lines with methylated EpCAM promoter showed a 60–80% reduction of EpCAM expression as determined at mRNA and protein level and exhibited a significantly reduced cell proliferation. Our data indicate that targeted methylation of the EpCAM promoter could be an approach in the therapy of EpCAM overexpressing cancers.

[1]  Albert Jeltsch,et al.  Targeted methylation and gene silencing of VEGF-A in human cells by using a designed Dnmt3a-Dnmt3L single-chain fusion protein with increased DNA methylation activity. , 2013, Journal of molecular biology.

[2]  T. Bestor,et al.  Cytosine methylation targetted to pre-determined sequences , 1997, Nature Genetics.

[3]  M. Rots,et al.  EpCAM in carcinogenesis: the good, the bad or the ugly. , 2010, Carcinogenesis.

[4]  M. Rots,et al.  Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer , 2012, Nucleic acids research.

[5]  Brigitte Mack,et al.  Nuclear signalling by tumour-associated antigen EpCAM , 2009, Nature Cell Biology.

[6]  I. Nagtegaal,et al.  The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. , 2003, The American journal of pathology.

[7]  K. Tai,et al.  DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression , 2007, Oncogene.

[8]  H. Moch,et al.  Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. , 2006, Gynecologic oncology.

[9]  L. Galluzzi,et al.  Molecular mechanisms of cisplatin resistance , 2012, Oncogene.

[10]  Pernette J. Verschure,et al.  Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes , 2012, Nucleic acids research.

[11]  Peter A. Jones Functions of DNA methylation: islands, start sites, gene bodies and beyond , 2012, Nature Reviews Genetics.

[12]  James E. Frampton Catumaxomab: in malignant ascites. , 2012, Drugs.

[13]  A. Jeltsch,et al.  Structure and Function of Mammalian DNA Methyltransferases , 2011, Chembiochem : a European journal of chemical biology.

[14]  Y. Hannun,et al.  EpCAM Is Overexpressed in Breast Cancer and Is a Potential Target for Breast Cancer Gene Therapy , 2004, Cancer Research.

[15]  M. Rots,et al.  Bidirectional modulation of endogenous EpCAM expression to unravel its function in ovarian cancer , 2013, British Journal of Cancer.

[16]  Tom H. Pringle,et al.  The human genome browser at UCSC. , 2002, Genome research.

[17]  Howard Cedar,et al.  Programming of DNA methylation patterns. , 2012, Annual review of biochemistry.

[18]  W. Parson,et al.  Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue. , 2007, Cancer letters.

[19]  Aaron Klug,et al.  In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence , 1994, Nature.

[20]  C. Barbas,et al.  ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. , 2013, Trends in biotechnology.

[21]  M. Rots,et al.  Engineering zinc finger protein transcription factors to downregulate the epithelial glycoprotein‐2 promoter as a novel anti‐cancer treatment , 2007, Molecular carcinogenesis.

[22]  T. Raum,et al.  A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. , 2006, European journal of cancer.

[23]  H. A. Bakker,et al.  Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule , 1994, The Journal of cell biology.

[24]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[25]  S. Cannistra Cancer of the ovary. , 1993, The New England journal of medicine.

[26]  A Klug,et al.  Toward a code for the interactions of zinc fingers with DNA: selection of randomized fingers displayed on phage. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Barbas,et al.  Building zinc fingers by selection: toward a therapeutic application. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Pilar Blancafort,et al.  Epigenetic reprogramming of cancer cells via targeted DNA methylation , 2012, Epigenetics.

[29]  R. Reinhardt,et al.  DNA methylation analysis by bisulfite conversion, cloning, and sequencing of individual clones. , 2009, Methods in molecular biology.

[30]  Tim Hui-Ming Huang,et al.  Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  J. Barnholtz-Sloan,et al.  Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. , 2003, American journal of obstetrics and gynecology.

[32]  D J Segal,et al.  Design of polydactyl zinc-finger proteins for unique addressing within complex genomes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Alessandro Lugli,et al.  Frequent EpCam protein expression in human carcinomas. , 2004, Human pathology.

[34]  W. Duan,et al.  RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule , 2011, Cancer science.

[35]  J. Thiery The saga of adhesion molecules , 1996, Journal of cellular biochemistry.

[36]  R. Kimmig,et al.  Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer. , 2009, Anticancer research.

[37]  Lalit Kumar,et al.  Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer , 2006, Indian Journal of Medical and Paediatric Oncology.

[38]  D. Seimetz,et al.  Catumaxomab: clinical development and future directions. , 2010, mAbs.

[39]  Margaret Gardiner-Garden,et al.  Overexpression of the Cell Adhesion Molecules DDR1, Claudin 3, and Ep-CAM in Metaplastic Ovarian Epithelium and Ovarian Cancer , 2004, Clinical Cancer Research.

[40]  Albert Jeltsch,et al.  BISMA - Fast and accurate bisulfite sequencing data analysis of individual clones from unique and repetitive sequences , 2010, BMC Bioinformatics.

[41]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[42]  Erin L. Doyle,et al.  Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting , 2011, Nucleic acids research.

[43]  Stefan Sleijfer,et al.  Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. , 2009, Cancer treatment reviews.

[44]  M. Rots,et al.  Persistent downregulation of the pancarcinoma‐associated epithelial cell adhesion molecule via active intranuclear methylation , 2008, International journal of cancer.

[45]  M. Rots,et al.  Targeted DNA Methylation by a DNA Methyltransferase Coupled to a Triple Helix Forming Oligonucleotide To Down-Regulate the Epithelial Cell Adhesion Molecule , 2010, Bioconjugate chemistry.

[46]  C. Bokemeyer Catumaxomab – trifunctional anti-EpCAM antibody used to treat malignant ascites , 2010, Expert opinion on biological therapy.

[47]  L. Schwartzberg Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. , 2001, Critical reviews in oncology/hematology.

[48]  A. Jeltsch,et al.  Silencing of gene expression by targeted DNA methylation: concepts and approaches. , 2010, Methods in molecular biology.

[49]  S H Kim,et al.  In vitro selection of zinc fingers with altered DNA-binding specificity. , 1994, Biochemistry.

[50]  M. Pensabene,et al.  New Hypothesis on Pathogenesis of Ovarian Cancer Lead to Future Tailored Approaches , 2013, BioMed research international.

[51]  A. Bird,et al.  DNA methylation landscapes: provocative insights from epigenomics , 2008, Nature Reviews Genetics.

[52]  C. Bokemeyer,et al.  Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. , 2010, Cancer treatment reviews.

[53]  A. Bogdanove,et al.  TAL Effectors: Customizable Proteins for DNA Targeting , 2011, Science.

[54]  M. Rots,et al.  Transcription factors and molecular epigenetic marks underlying EpCAM overexpression in ovarian cancer , 2011, British Journal of Cancer.

[55]  S. Leung,et al.  Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.

[56]  A. Plückthun,et al.  Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy , 2013, Expert opinion on drug delivery.

[57]  Markus Münz,et al.  The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation , 2004, Oncogene.

[58]  Albert Jeltsch,et al.  Chimeric DNA methyltransferases target DNA methylation to specific DNA sequences and repress expression of target genes , 2006, Nucleic acids research.

[59]  C. Pabo,et al.  Zinc finger phage: affinity selection of fingers with new DNA-binding specificities. , 1994, Science.

[60]  R. Kimmig,et al.  Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells , 2003, Journal of Cancer Research and Clinical Oncology.

[61]  A. Jeltsch,et al.  Application of DNA methyltransferases in targeted DNA methylation , 2007, Applied Microbiology and Biotechnology.

[62]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[63]  J. Berek,et al.  Ovarian cancer: epidemiology, biology, and prognostic factors. , 2000, Seminars in surgical oncology.

[64]  Julie A. Law,et al.  Establishing, maintaining and modifying DNA methylation patterns in plants and animals , 2010, Nature Reviews Genetics.

[65]  G. Schäfer,et al.  Overexpression of Epithelial Cell Adhesion Molecule Antigen in Gallbladder Carcinoma Is an Independent Marker for Poor Survival , 2004, Clinical Cancer Research.

[66]  O. Gires,et al.  EpCAM (CD326) finding its role in cancer , 2007, British Journal of Cancer.

[67]  P. Went,et al.  EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis , 2011, Journal of Clinical Pathology.